Takeaways
- Limited comparative research exists on the levonorgestrel IUD for endometrial protection, highlighting a need for larger international trials.
- The IUD provides effective endometrial protection, reliable contraception, and minimal…
Traders work on the floor of the New York Stock Exchange during afternoon trading on Oct. 14, 2025 in New York City.
Michael M. Santiago | Getty Images
The S&P 500 rose on Thursday, boosted by tech stocks, as investors stepped in to buy after a batch of strong earnings results.
The broad market index climbed 0.58% to close at 6,738.44, while the Dow Jones Industrial Average traded up 144.20 points, or 0.31%, to finish at 46,734.61. The Nasdaq Composite outperformed, rising 0.89% to settle at 22,941.80, seeing support from the gains in names like Nvidia, Broadcom and Amazon. A nearly 3% jump in shares of fellow artificial intelligence player Oracle also helped send the market higher.
Averages hit their highs of the session after White House press secretary Karoline Leavitt said during a press briefing that President Donald Trump will meet with Chinese President Xi Jinping next Thursday in South Korea. The announcement eased investors’ fears about U.S.-China relations that had pressured equities on Wednesday.
The S&P 500’s move higher marks a full recovery and more from its meaningful losses seen in the previous session, when the index fell roughly 0.5%. The Dow lost about 334 points, or 0.7%, while the Nasdaq declined 0.9% as investors rotated out of riskier assets.
Stocks had finished lower Wednesday after Treasury Secretary Scott Bessent confirmed the White House is mulling plans to curb exports to China made with U.S. software. Those plans would build on Trump’s statement almost two weeks ago that the U.S. will implement export restrictions by Nov. 1 on “any and all critical software.”
“Do not discount the bull market yet, just because of a volatility bout,” said Giuseppe Sette, co-founder and president at Reflexivity. “A handful of tech stocks have led the rally, but now we stand to see how hundreds of global companies benefit from AI’s productivity gains.”
Investors are continuing to watch earnings releases from key U.S. companies, which many believe could be make-or-break for the current bull market rally. Honeywell shares led the blue-chip Dow’s rise, advancing almost 7% Thursday, after it posted better-than-expected quarterly results and lifted its full-year outlook. American Airlines increased 6% following its narrower-than-expected third-quarter loss and upbeat guidance.
The market was able to overcome what had been sore spots in the trading day. Tesla – which kicked off reports from the “Magnificent Seven” – ended up 2% after coming back from earlier losses following a mixed third-quarter report. IBM shares also pared losses after beating Wall Street estimates but reporting in-line software revenue. Meanwhile, oil prices rose after the Trump administration imposed new sanctions on Russia’s two biggest crude companies due to the country’s “lack of serious commitment to a peace process to end the war in Ukraine.”
More than 80% of the S&P 500 companies that have reported so far have exceeded earnings expectations, per FactSet.
“While we are seeing individual stocks get punished after missing expectations, we expect earnings overall to be strong enough to keep stock prices elevated in the near-term,” said Emily Bowersock Hill, CEO and founding partner at Bowersock Capital Partners. “This current earnings season is unlikely to disappoint investors enough to trigger a notable market setback.”
Beyond earnings, inflation data due Friday is expected to give further clues about the health of the economy, particularly ahead of the Federal Reserve’s late October meeting. Markets widely expect central bankers to cut rates by another quarter percentage point.
Vladimir Putin has said Russia will never bow to US pressure but conceded new sanctions could cause some economic pain, as China and India were reported to be scaling back Russian oil imports after Washington targeted Moscow’s two largest…
OpenAI introduced its own web browser, Atlas, on Tuesday, putting the ChatGPT maker in direct competition with Google as more internet users rely on artificial intelligence to answer their questions.
Making its popular…
For people with schizophrenia, hearing voices can feel vividly real – but why this happens has remained a mystery.
A recent study by the University of New South Wales (UNSW) showed that the brain of someone experiencing auditory…
A recent study found that patients with both primary hyperoxaluria (PH) and chronic kidney disease (CKD) face greater healthcare costs as CKD stage progresses.1
The study, published in BMC Nephrology, was a retrospective administrative claims…
—Insmed Leads Science Top Employers List for Fifth Year in a Row—
BRIDGEWATER, N.J., Oct. 23, 2025 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science‘s 2025 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the companies with the best reputations as employers.
“It is an incredible privilege to see our organization recognized as the top employer in Science’s annual survey for a record five consecutive years—something only achieved once before when the list first began,” said Will Lewis, Chair and Chief Executive Officer of Insmed. “We are experiencing an extraordinary period of growth, driven by a series of clinical successes and regulatory milestones that support us in working toward our mission to transform the lives of patients with serious and rare diseases. This recognition reflects not only our deep commitment to advancing science, but also the passion and purpose that drive our work every day.”
The 2025 survey results were based on approximately 5,500 responses from individuals located primarily across North America (66%), Europe (20%), and Asia/Pacific Rim (9%). This year’s highest-ranking companies stood out in the areas of corporate image, financial prowess, leadership and direction, work culture and environment, and academic and intellectual challenge.
“Being recognized once again by Science as the top employer in the biopharma industry is a tremendous honor and a reflection of the people-first culture we continue to build at Insmed,” said Nicole Schaeffer, Chief People Strategy Officer of Insmed. “By fostering an environment where collaboration meets flexibility, we enable our talented team to drive scientific breakthroughs on behalf of patients with serious diseases. I’m grateful to every colleague who makes Insmed such a special place to work.”
The complete feature and company rankings can be accessed here. To learn more about Insmed’s culture, please visit https://insmed.com/company/culture/.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed’s most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company’s early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
[email protected]
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
[email protected]
SOURCE Insmed Incorporated
The Orionid meteor shower peaked on the nights of Oct. 21-23, delighting lucky stargazers with a gorgeous natural fireworks display as debris from Halley’s Comet collided with Earth’s atmosphere to create fiery shooting stars in the night…
This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!